<DOC>
	<DOCNO>NCT01845077</DOCNO>
	<brief_summary>The purpose trial demonstrate relative bioavailability 2 newly develop fix dose combination ( FDC ) tablets contain linagliptin &amp; metformin single tablet linagliptin metformin administer singularly .</brief_summary>
	<brief_title>Relative Bioavailability 2 Fixed Dose Combinations Linagliptin/Metformin Compared With Single Tablets</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male females 2 . Age 18 50 year ( incl ) 3 . Body Mass Index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) 4 . Subjects must able understand comply study requirement Exclusion criterion : Any deviation healthy condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>